Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06475820CT.gov Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis | — | Active Not Recruiting | — | — | — |
NCT05515029CT.gov Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | — | Active Not Recruiting | — | — | — |
NCT01012492CT.gov Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Biphenotypic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abatacept Recombinant (this asset) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P3 | B · 63 |
| Fludarabine | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P2/3 | BB |
| Cytarabine | University of Washington | P2 | BB |
| Nivestim | Ossium Health, Inc. | P2 | BB |
| Busulfanum | Ossium Health, Inc. | P2 | BB |
| Cyclophosphamide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P3 | BB |
| Thiotepa | Fred Hutchinson Cancer Center | P2 | BB |
| Cladribine | University of Washington | P2 | BB |
| Sorafenib | University of Washington | P2 | BB |
+42 more in the Acute Biphenotypic Leukemia cohort
Other indications for Abatacept Recombinant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P3 | BB · 68 |
| Primary Biliary Cholangitis | — | P4 | BB · 66 |
| Acute Myeloid Leukemia | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Abatacept Recombinant in Acute Biphenotypic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/abatacept-recombinant-acute-biphenotypic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →